BIIB250110C155000
- 0.03
- -0.21-87.50%
Biogen Newsroom
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
Biogen Analyst Ratings
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $165
Wells Fargo Issues a Hold Rating on Biogen (BIIB)
Truist has lowered the Target Price for Bogen to $220.
Biogen Is Maintained at Buy by Truist Securities
Biogen Analyst Ratings
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $220
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $231
Guggenheim Adjusts Price Target on Biogen to $190 From $245, Maintains Buy Rating
Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler
Biogen Analyst Ratings
BMO Capital has lowered the Target Price and rating for Bojian.
Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290
BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164
Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles
Biogen Cut to Market Perform From Outperform by BMO Capital
Biogen Analyst Ratings
BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164
Stifel Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $175